EUVIMEDEUVIMED entdecken
Crossref

Tafro syndrome: early combination therapy outcomes and prolonged thrombocytopenia—a seven-case series

Shiro Ono iD, Tomohiro Nakamura, Nobushiro Nishimura iD, Hidetoshi Matsuoka, Ryo Yoneima iD, Hiromasa Kawashima iD, Makiko Miyamoto, Masaki Matsubara iD, Noritaka Yada iD, Kiyomi Yoshimoto iD

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Shiro Ono und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Thrombocytopenia, Castleman Disease. Die Arbeit nennt 42 Literaturangaben. Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate treatment outcomes, complications, and the clinical course of thrombocytopenia in patients with TAFRO syndrome.

Methods

We conducted a retrospective analysis of patients treated at Nara Medical University Hospital from 2015 to 2023. Diagnosis of TAFRO syndrome was made according to the 2015 or 2019 criteria, and disease severity was assessed based on the updated disease severity classification. Clinical characteristics and laboratory and histological data were analysed.

Results

Seven patients were included, with four classified as very severe, two as severe, and one as slightly severe. All the patients received early combination therapy (various combinations of glucocorticoids, tocilizumab, cyclosporine, and rituximab), with the second therapy added a median of 5 days after the first. Six patients received eltrombopag. Despite intensive treatment, thrombocytopenia persisted for a prolonged period, with a median time to platelet count normalization of 54 days. Cytomegalovirus reactivation occurred in six patients during treatment but resolved with appropriate antiviral therapy. All the patients achieved remission and survived.

Conclusions

Thrombocytopenia in TAFRO syndrome persists long term despite intensive combination therapy. Early combination therapy was associated with excellent survival outcomes, suggesting that intensifying treatment solely for thrombocytopenia may not be necessary given its prolonged course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaCastleman DiseaseHumansMaleFemaleRetrospective StudiesMiddle AgedDrug Therapy, CombinationAdultRituximabAgedGlucocorticoidsHydrazinesTreatment OutcomeAntibodies, Monoclonal, HumanizedCyclosporinePyrazolesBenzoates

Stichwörter der Autor:innen

Anti-interleukin 6 receptorTAFRO syndromecombination therapycyclosporineiMCD-TAFROrituximabthrombocytopenia

Substanzen

RituximabGlucocorticoidseltrombopagHydrazinesAntibodies, Monoclonal, HumanizedtocilizumabCyclosporinePyrazolesBenzoates

Autor:innen und Institutionen

  • Department of General Medicine, Nara Medical University, Nara, Japan.

ORCID-Profile: Shiro Ono, Nobushiro Nishimura, Ryo Yoneima, Hiromasa Kawashima, Masaki Matsubara, Noritaka Yada, Kiyomi Yoshimoto

Förderung

  • JSPS KAKENHI

Zitieren

APA

Ono, S., Nakamura, T., Nishimura, N., Matsuoka, H., Yoneima, R., Kawashima, H., Miyamoto, M., Matsubara, M., Yada, N., & Yoshimoto, K. (2025). Tafro syndrome: early combination therapy outcomes and prolonged thrombocytopenia—a seven-case series. Modern Rheumatology. https://doi.org/10.1093/mr/roaf092

Vancouver

Ono S, Nakamura T, Nishimura N, Matsuoka H, Yoneima R, Kawashima H, et al. Tafro syndrome: early combination therapy outcomes and prolonged thrombocytopenia—a seven-case series. Modern Rheumatology. 2025. doi:10.1093/mr/roaf092

BibTeX
@article{Ono2025,
  author = {Ono, Shiro and Nakamura, Tomohiro and Nishimura, Nobushiro and Matsuoka, Hidetoshi and Yoneima, Ryo and Kawashima, Hiromasa and Miyamoto, Makiko and Matsubara, Masaki and Yada, Noritaka and Yoshimoto, Kiyomi},
  title = {Tafro syndrome: early combination therapy outcomes and prolonged thrombocytopenia—a seven-case series},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf092}
}
Kostenlos starten →